Welcome to the e-CCO Library!

P384: Therapeutic drug monitoring: performance of the first lateral flow-based Point of Care test for the quantification of infliximab in a finger prick
Year: 2021
Source: ECCO'21 Virtual
Authors: Ametzazurra, A.(1);Pascual, J.(1);Del Rio, L.(1);Maguregui, A.(1);Nagore, D.(1);Ruiz-Argüello, M.B.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P385 A mucosal marker predicting tofacitinib induced an endoscopic response in ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Verstockt1, S. Verstockt2, D. Alsaoud2, J. Sabino1, M. Ferrante1, S. Vermeire1

Created: Thursday, 30 January 2020, 10:12 AM
P385: Assessment of long-term outcomes of patients with ulcerative colitis and mucosal healing under different therapies: Is all mucosal healing the same?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Raimundo Fernandes S.*1, Correia L.1, Baldaia C.2, Moura Santos P.2, Rita Gonçalves A.2, Valente A.2, Velosa J.1

Created: Wednesday, 20 February 2019, 10:36 AM
P385: Colectomy-free survival and factors associated with it in children with ulcerative colitis managed in a tertiary IBD centre in the UK
Year: 2018
Source: ECCO '18 Vienna
Authors:

S.-Y. Ong*, W. Haller, R. Muhammed

Created: Thursday, 21 February 2019, 9:14 AM
P385: Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

N. Viazis*1, M. Giakoumis1, G. Bamias2, D. Goukos2, T. Koukouratos1, J. Anastasiou1, K. Katopodi1, S. Ladas2, D. Karamanolis1

Created: Friday, 22 February 2019, 9:49 AM
P385: Results of a teleconsultation campaign for Inflammatory Bowel Disease (IBD) patients to check their treatment adherence and assess their level of anxiety during the first COVID-19 lockdown
Year: 2021
Source: ECCO'21 Virtual
Authors: Paupard, T.(1);richez, C.(2);verlynde, J.(1);zaharia, O.(1);quartier, G.(1);hudziak, H.(1);delhoustal, L.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P385: Risk-benefit assessment of IBD drugs: a physicians and patients survey
Year: 2023
Source: ECCO’23 Copenhagen
Authors: D'Amico, F.(1)*;Caron, B.(2);Vieujean, S.(3);Peyrin-Biroulet, L.(2);Danese, S.(1);
Created: Friday, 14 July 2023, 11:05 AM
P385: Tailoring induction treatment for children with Crohn’s disease.
Year: 2022
Source: ECCO'22
Authors: Cuomo, M.(1);Carobbio, A.(2);Aloi , M.(3);Alvisi , P.(4);Banzato, C.(5);Bosa, L.(6);Bramuzzo, M.(7);Campanozzi, A.(8);Catassi , G.(3);D'Antiga, L.(2);Di Paola, M.(9);Felici, E.(10);Fioretti , M.T.(11);Gatti , S.(12);Graziano, F.(13);Lega , S.(7);Lionetti , P.(9);Marseglia , A.(14);Martinelli , M.(11);Musto, F.(15);Sansotta, N.(2);Scarallo , L.(9);Zuin, G.(15);Norsa, L.(16);
Created: Friday, 11 February 2022, 3:52 PM
P385: TREM1, the first anti-TNF specific biomarker guiding therapeutic decision
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Verstockt*1,2, S. Verstockt3, J. Dehairs4, V. Ballet1, H. Blevi2, W-J. Wollants2, C. Breynaert5, G. Van Assche1,2, S. Vermeire1,2, M. Ferrante1,2

Created: Friday, 22 February 2019, 9:41 AM
P386 Long-term evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (IBD): A multicentre study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.J. Casanova1, M. Chaparro2, O. Nantes3, J.M. Benítez4, M. Rojas-Feria5, J. Castro-Poceiro6, J.M. Huguet7, A. Martín-Cardona8, M. Aicart9, J. Tosca10, M.D.M. Martín-Rodríguez11, C. González-Muñoza12, M. Mañosa13, E. Leo-Carnerero14, L. Lamuela15, I. Pérez-Martínez16, L. Bujanda17, J. Hinojosa18, R. Pajares19, F. Argüelles-Arias20, J.L. Pérez-Calle21, G.E. Rodríguez-González22, J. Guardiola23, M. Barreiro-de Acosta24, F. Bermejo25, J. Barrio26, B. Beltrán27, F. Gomollón28, R. Lorente29, A. Gutierrez30, M. Domínguez-Cajal31, C. Dueñas32, A. Ponferrada-Díaz33, M. Van Domselaar34, P. Ramírez-de la Piscina35, L. Ramos36, P. Almela37, M. Navarro-Llavat38, B. Botella39, J.P. Gisbert2, EVODIS

Created: Thursday, 30 January 2020, 10:12 AM
P386: A target 6-thioguanine nucleotide ≥125 is associated with a higher rate and longer durability of response in infliximab–thiopurine combination therapy: a retrospective study in Crohn's disease patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Luber R.*1,2, Kariyawasam V.3, Dawson L.1, Munari S.1, Gibson P.1,2, Sparrow M.1,2, Ward M.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P386: Anti-TNF alpha as induction and maintenance therapy in ulcerative colitis patients in the BioColitis Registry in Germany
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

B. Bokemeyer*1, T. Krummenerl2, C. Maaser3, J. Büning4, R. Atreya5, A. Lügering6, U. Helwig7, P. Jessen8, P. Hartmann9, S. Schreiber10

Created: Friday, 22 February 2019, 9:49 AM
P386: Association of Infliximab trough levels and perianal disease activity in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Simões*1, S. Fernandes1, S. Bernardo1, A. R. Gonçalves1, C. Baldaia1, A. Valente1, P. Moura Santos1, L. Correia1, R. Tato Marinho1

Created: Friday, 22 February 2019, 9:41 AM
P386: Clinical presentation, management, and evolution of lymphomas in patients with Inflammatory Bowel Disease: an ENEIDA registry study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Guerra Marina, I.(1)*;Bujanda, L.(2,3);Mañosa, M.(3,4);Pérez-Martínez, I.(5);Casanova, M.J.(3,6);de la Peña, L.(7);de Benito, M.(8);Rivero, M.(9);Varela, P.(10);Bernal, L.(3,11);Franco, A.C.(12);Ber, Y.(13);Piqueras, M.(14);Tardillo, C.(15);Ponferrada, Á.(16);Olivares, S.(17);Lucendo, A.J.(18);Gilabert, P.(19);Sierra Ausín, M.(20);Bellart, M.(1);Herrarte, A.(2);Calafat, M.(3,4);de Francisco, R.(5);P. Gisbert, J.(3,6);Guardiola, J.(7);Domènech, E.(3,4);Bermejo, F.(1);
Created: Friday, 14 July 2023, 11:05 AM
P386: Methotrexate use in combination with anti-TNFα agents in IBD: A tertiary centre experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

W. Waddingham*, A. Nwaogu, E. Michael, L. Whitley, H. Parker, R. Kettle, I. Parisi, E. Seward, S. McCartney, S. Bloom, R. Vega, F. Rahman, S. Mehta

Created: Thursday, 21 February 2019, 9:14 AM
P386: Predictive models for assessing the response to ustekinumab in Crohn’s disease patients
Year: 2022
Source: ECCO'22
Authors: Hubert, A.(1);Bottieau, J.(1);Toubeau, J.F.(1);Franchimont, D.(2,3);Vallée, F.(1);Liefferinckx, C.(2,3);
Created: Friday, 11 February 2022, 3:52 PM
P386: Two year follow up of children with Inflammatory Bowel Disease (IBD) treated with vedolizumab and ustekinumab
Year: 2021
Source: ECCO'21 Virtual
Authors: Mardare, R.(1);Burgess, N.(1);Studart, D.(1);Deb, P.(1);Gasparetto, M.(1);Croft, N.(1);Naik, S.(1);Kadir, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P387 Real-world clinical outcomes of biologic-naïve non-complicated Crohn’s disease patients treated with vedolizumab: Results from the EVOLVE study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Yarur1, G.J. Mantzaris2, U. Kopylov3, M. Bassel4, N. Brett4, H. Kim5, C. Lopez6, S. Saha7, C. Kifnidi8, C. Agboton9, S. Adsul9, D. Demuth10, M. Luo11, S. Wang11, B. Bressler12

Created: Thursday, 30 January 2020, 10:12 AM
P387: Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic
Year: 2021
Source: ECCO'21 Virtual
Authors: Lin, S.(1,2);Bewshea, C.(2);Chanchlani, N.(2);Chee, D.(1,2);Pollok, R.C.(3,4);Kennedy, N.A.(1,2);Ahmad, T.(1,2);Goodhand, J.R.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P387: Different rate of transmural remission between first and second line of biologic treatment in Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: De Sire, R.(1)*;Rispo, A.(1);Caiazzo, A.(1);Testa, A.(1);Nardone, O.M.(1);Guarino, A.D.(1);Olmo, O.(1);Calabrese, G.(1);Fierro, G.(1);Toro, B.(1);Cantisani, N.M.(1);Ferrante, M.(1);La Mantia, A.(1);D'Alessandro, E.(1);Castiglione, F.(1);
Created: Friday, 14 July 2023, 11:05 AM